Advertiser / Brand
Kimberly-Clark vs Revolution Beauty
Structured technology and market comparison · 2026
Direct Feature Comparison
Kimberly-Clark · vs · Revolution BeautyConsumer goods manufacturer focused on tissue, hygiene and personal care.
Public beauty brand selling makeup, skincare and haircare products.
Analyze all overlapping signals and tech stacks for Kimberly-Clark and Revolution Beauty
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between Kimberly-Clark and Revolution Beauty?
When comparing Kimberly-Clark and Revolution Beauty, both platforms operate within the Advertiser / Brand ecosystem. Kimberly-Clark is positioned as Consumer goods manufacturer focused on tissue, hygiene and personal care, whereas Revolution Beauty focuses on Public beauty brand selling makeup, skincare and haircare products. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to Kimberly-Clark and Revolution Beauty?
When evaluating Kimberly-Clark and Revolution Beauty, enterprise buyers also consider other platforms in Advertiser / Brand. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of Kimberly-Clark and Revolution Beauty compare?
Kimberly-Clark is headquartered in United States (founded in 1872) with >5,000 employees. Revolution Beauty is based in United Kingdom (founded in 2014) with 201–500 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: Kimberly-Clark vs Revolution Beauty
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
Kimberly-Clark
Recent Signals
- ·SEC APIfinancials
8-K Financial Filing Analysis for Kimberly-Clark (2026-11-05)
On November 5, 2026, Kimberly-Clark Corporation filed a Current Report on Form 8-K under Item 2.02 (Results of Operations and Financial Condition) announcing its financial results for the third quarter ended September 30, 2026. The detailed financial press release was furnished as Exhibit 99.1. In accordance with standard SEC furnishing rules, the information and accompanying exhibit are not deemed 'filed' for liability purposes under Section 18 of the Exchange Act, nor are they incorporated by reference into registration statements under the Securities Act of 1933.
- Kimberly-Clark Corporation furnished its quarterly earnings release for the period ended September 30, 2026, via Exhibit 99.1 on November 5, 2026.
- The filing was executed under Item 2.02 by Senior Vice President and Chief Financial Officer Nelson Urdaneta.
- Information provided in the filing is formally furnished rather than filed, excluding it from Section 18 liabilities of the Securities Exchange Act of 1934.
- ·SEC APIfinancials
8-K Financial Filing Analysis for Kimberly-Clark (2026-11-02)
On November 2, 2026, Kimberly-Clark Corporation (K-C) completed its acquisition of Kenvue Inc. Under the merger terms, Kenvue shareholders received $3.50 in cash and 0.14625 shares of K-C common stock per share, requiring K-C to issue approximately 281,060,840 common shares. In connection with the transaction, K-C's Board approved the Kenvue Integration Program through December 31, 2029, expecting cumulative pre-tax restructuring and integration charges of approximately $3.1 billion ($2.5 billion in cash and $0.6 billion non-cash) alongside $1.4 billion in related capital expenditures to achieve targeted operational synergies by 2030. Governance and compensatory actions accompanying the close include the appointment of three former Kenvue directors—Richard E. Allison, Jr., Larry J. Merlo, and Kirk L. Perry—to K-C's Board, replacing three resigning directors. Furthermore, K-C granted premium-priced, nonqualified stock options to executive leadership, including $6.6 million in grant value to CEO Michael Hsu, with exercise prices set at a minimum of $120.00 or 110% of the grant-date stock price, vesting December 1, 2029.
- K-C completed the acquisition of Kenvue Inc., issuing approximately 281,060,840 K-C common shares and paying $3.50 in cash plus 0.14625 K-C shares per Kenvue share.
- The Board approved the Kenvue Integration Program through December 31, 2029, projecting $3.1 billion in pre-tax charges ($2.5 billion cash, $0.6 billion non-cash) and $1.4 billion in capital expenditures.
- Three Kenvue directors were appointed to K-C's Board (replacing three resigning directors), and executives were awarded premium-priced stock options (including $6.6M in grant value to CEO Michael Hsu) with exercise prices at the greater of $120.00 or 110% of the Grant Date market price.
- ·SEC APIfinancials
8-K Financial Filing Analysis for Kimberly-Clark (2026-11-04)
On November 4, 2026, Kimberly-Clark Corporation completed private exchange offers and consent solicitations covering $7.0 billion aggregate principal amount of senior notes originally issued by Kenvue Inc. The transaction follows the November 2, 2026 closing of Kimberly-Clark's merger with Kenvue, in which Kenvue became a direct wholly owned subsidiary (renamed Kenvue LLC). In the exchange offers, Kimberly-Clark accepted and canceled approximately $6.376 billion of Kenvue notes in exchange for newly issued, pari passu Kimberly-Clark senior notes across seven tranches maturing between 2028 and 2063 with coupon rates from 4.850% to 5.200%. Concurrent amendments stripped substantially all restrictive covenants, default provisions, and SEC reporting requirements from the remaining $623.66 million of unexchanged Kenvue notes.
- Kimberly-Clark completed the exchange of $6,375,992,000 across seven tranches of Kenvue senior notes into new Kimberly-Clark senior notes with matching maturities (2028-2063) and interest rates (4.850%-5.200%).
- A total of $623,661,000 in aggregate principal amount of Kenvue notes remains outstanding across seven series following the settlement.
- The operative Third Supplemental Indenture stripped substantially all restrictive covenants, certain events of default, and SEC reporting obligations from remaining Kenvue notes.
Revolution Beauty
Recent Signals
- ·SEC APIfinancials
8-K Financial Filing Analysis for Revolution Beauty (2026-08-19)
On August 17, 2026, the Compensation Committee of Revelation Biosciences, Inc. approved material restricted stock grants to executive leadership under its Amended and Restated 2021 Equity Incentive Plan. Chief Executive Officer James Rolke received 208,076 restricted shares, and Chief Financial Officer Chester S. Zygmont, III was granted 208,073 restricted shares. The equity awards are structured to vest across four equal 25% tranches linked to either reaching market capitalization hurdles of $30 million, $60 million, $90 million, and $120 million for 20 consecutive trading days, or time-based vesting at the two-year and four-year marks. The package aligns executive compensation with aggressive market valuation targets while providing retention security.
- CEO James Rolke and CFO Chester S. Zygmont, III were granted 208,076 and 208,073 restricted shares, respectively, under the 2021 Equity Incentive Plan.
- Awards vest in four equal 25% tranches upon reaching market capitalization thresholds of $30M, $60M, $90M, and $120M sustained over 20 consecutive trading days, or alternatively at 2-year (first two tranches) and 4-year (final two tranches) time intervals.
- Grants include standard accelerated vesting protections upon a Change in Control or qualified involuntary termination events.
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners Kimberly-Clark and Revolution Beauty share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks